T he symptoms and signs of Cushing' s synd d drome result directly from chronic exposure to excess glucocorticoids. Most actions of glucocorticoids are mediated by the glucocorticoid red d ceptor. Several polymorphisms in the gene coding for the glucocorticoid receptor have been described and these may contribute considerably to the observed varid d ability in glucocorticoid sensitivity. 1 At the tissue level, the enzyme 11βdhydroxysteroid dehydrogenase type I modulates the effect of glucocorticoids. Both animal and human studies have demonstrated that alterations in 11βdhydroxysteroid dehydrogenase type I activity in adipose tissue and liver are associated with the metad d bolic syndrome, thus possibly reflecting a tissuedspecific (omental) Cushing' s syndrome. 2 . Cellular hyperreactivd d ity to glucocorticoids at the mRNA level has also been demonstrated. 3 It is not surprising, therefore, that cases of Cushing' s syndrome with putative receptor dysfuncd d tion exist, and we report one such likely case and review the literature on this topic.
Case
A 32dyeardold female was referred to our department in August 2000 for evaluation of cushingoid features. She gave a history of recurrent abdominal pain and renal stones from 1987 to1993. Hypertension and diabetes mellitus were diagnosed in 1994 and she had since been on treatment with lisinopril and insulin. In 1995, her treating doctor observed that she had clinical features of Cushing' s syndrome. Evaluation of her condition then revealed very low serum cortisol levels without diurnal variation and undetectable 24dhour urinary cortisol. CT of her adrenals demonstrated a picture suggestive of left supradrenal myelolipoma while MRI of the pid d tuitary was normal. In November 1995, she went to a private practice where she underwent left adrenalecd d tomy (with unavailable histopathology report) and was replaced with glucocorticoids for one year for a short period of time. Thereafter she received no glucocortid d coids or other steroiddcontaining drugs. Occasionally she complained of difficulty in standing from a sitting or lying position without aid. She had normal and regud d lar menses.
On examination she was conscious, oriented, and her blood pressure was moderately high (150/110 mm Hg) with a regular and normal pulse rate. She had a round plethoric face with an increased amount of sud d praclavicular fat. She was centrally obese with thin exd d tremities and her skin was thin with purple striae on the abdomen. She had proximal muscle weakness in the lower limbs. Axillary and pubic hairs were presd d ent and she was not hirsute. The thyroid was not end d larged. The rest of her examination was unremarkable. Her workdup demonstrated undetectable cortisol in a 24dhour urine (repeated twice). The morning cortisol at 8 AM was low at 28 nmol/L (repeated twice) and the morning adrenocorticotropic hormone (ACTH) at 8 AM was low at <10 pg /mL (normal range, 10d46 pg /mL). There was a very poor cortisol response to the synacthen (ACTH 
DIsCUssION
The glucocorticoid receptor is a ligandddependent trand d scriptional regulator that mediates a panoply of develd d opmental, physiological, and behavioral processes. 4 The glucocorticoid receptor is not the sole determinant of the cellular response to ligands; other cellular factors are known to modulate glucocorticoid receptor acd d tion. For example, hormone transporters, 5,6 molecular chaperones, 7 chromatin remodeling factors, 8, 9 coactid d vators, 10 as well as other transcription factors such as APd1 11 interact with the glucocorticoid receptor and affect its function. Mutations of the glucocorticoid receptor result in syndromes of local and generalized glucocorticoid resistance, glucocorticoid hypersensitivd d ity, hypercortisolism, and increased cortisol response to stress. 12 Whereas decreased sensitivity to the corticod d steroid receptor is described more frequently, Iida and colleagues first described increased sensitivity to the glucocorticoid receptor in 1990 13 in a patient that had clinical characteristics of Cushing' s syndrome and low cortisol concentrations on several occasions. Exogenous corticosteroids were the best explanation for the clinid d cal picture and laboratory abnormalities, but this could not be confirmed and the patient' s history lacked any information. Other possibilities that should have been considered include intermittent Cushing' s syndrome, promiscuous receptordinduced Cushing' s syndrome and silent pituitary infarction of ACTHdproducing adenoma. Intermittent Cushing' s was excluded by the lack of raised cortisol levels (urine and serum) on red d peated measurements at different intervals, whereas promiscuous receptordinduced Cushing' s could not be confirmed. Silent pituitary infarction was also excluded by the normal level of anterior lobe pituitary hormones and by the normal pituitary gland by MRI. The authors therefore considered a cortisol hyperreactive syndrome as a plausible possibility in this patient. In vitro experid d ments with the patient' s skin fibroblasts supported the concept of an increased sensitivity to glucocorticoids. More recently, Huizenga and colleagues 14 described a polymorphism in the glucocorticoid receptor that was associated with increased receptor sensitivity. In that study, 13 patients carrying a mutation in the glucocord d ticoid receptor (N363S carriers) were identified. The patients with this mutation had a significantly higher body mass index (BMI) and there was a trend towards a lower bone mineral density, which suggests that they were more sensitive to the effects of glucocorticoids. A lowddose dexamethasone suppression test, using 0.25 mg instead of 1 mg dexamethasone, demonstrated sigd d nificantly larger cortisol suppression in the N363S card d riers.
14 Another case has been described by Newfield and colleagues of cushingoid features in prepuberty in the presence of normal cortisol levels. This patient was subsequently reported to have markedly elevated glucocorticoid receptor sites per peripheral lymphocyte with normal binding affinity as a potential cause of her phenotype.
15
In another report, a patient who received two intrad articular triamcinolone acetonide injections developed the clinical characteristics of Cushing' s syndrome and had asymptomatic adrenal insufficiency, which red d solved after 6 months. Therefore, increased sensitivity may also be subclinical and manifest after exposure to exogenous glucocorticoids. In this patient, a dexad d methasone suppression test, using 0.25 mg instead of 1 mg dexamethasone, demonstrated a significant decrease in the morning cortisol. The response of ped d ripheral blood mononuclear cells to dexamethasone in a mitogendstimulated proliferation assay in this patient showed a lower IC50 than normal controls, supportd d ing the diagnosis of increased glucocorticoid sensitivd d ity. 16 Hyperreactivity of our patient to glucocorticoids, either at the receptor or at the postdreceptor level could explain her cushingoid features if she had ingested even very small amounts of glucocorticoids. However, her hypocortisolemia predates her adrenal surgery and glucocorticoid use suggesting that she had overt actid d vation of the glucocorticoid receptor (or postdreceptor mechanisms).
The diagnosis of hypocortisolemic Cushing' s synd d drome is based on clinical suspicion, followed by docud d mentation that low cortisol levels are not associated with steroid intake. In our patient we documented a low cortisol level, a flat response to ACTH stimulation, no response to the CRH stimulation test and after a careful history, observation and intensive investigation, we excluded any possible steroid intake. In Cushing' s disease, the chronic hypercortisolemia inhibits hypod d thalamic CRH secretion and also inhibits ACTH sed d cretion by the normal, nonadenomatous pituitary cord d ticotrophs, which atrophy. The concentrations of CRH in the cerebrospinal fluid, and presumably in the hyd d pophysialdportal circulation, are reduced. 17 Also, exogd d enous glucocorticoids inhibit CRH and ACTH secred d tion, causing bilateral adrenocortical atrophy. Plasma ACTH, serum and salivary cortisol concentrations, and urinary 17dhydroxycorticosteroids and cortisol excretion (unless cortisol is the steroid administered) are all low. 18 We suggest that in patients with wilddtype receptors, minimal amounts of glucocorticoids will suppress the hypothalamicdpituitarydadrenal axis effecd d tively. Although not reported before, we thought about the effect of lisinopril on aberrant receptors, but substid d tuting it with amlodipine resulted in no improvement in her clinical condition or her biochemical profile.
The possible approach to treatment of these pad d tients is the use of the progesterone and glucocorticoid receptor antagonist RUd486 (mifepristone), which is a potent antagonist of both of these receptors. It is the only drug administered to humans with these actions. 19 In normal subjects, it inhibits dexamethasone supd d pression and raises endogenous cortisol and ACTH values. 20 To date, RUd486 has been used in a handful of patients with Cushing' s syndrome. In a placebodcond d trolled trial of the acute effects in seven patients given 200 mg orally every 12 hours, plasma and urinary glud d cocorticoids were raised in five patients with Cushing' s disease after 2 days. 21 Other reports describe treatment of a few patients, with symptomatic improvement at doses of 5d20 mg/kg/day. 22d25 Prompt reversal of neud d ropsychiatric symptoms has been reported in two cases of hypercortisolemic psychosis. 24 However longdterm data are unavailable as the longest period of treatment reported was 10 weeks. 22 The main drawback with use of this agent is the induction of an iatrogenic cortisol deficiency state, but Addisonian crisis responds to a dose reduction. Because of its novel site of action, with receptor antagonism leading to increased cortisol and ACTH levels, the diagnosis of treatmentdinduced glucocorticoid insufficiency rests on clinical grounds. Limited clinical experience with RUd486 in Cushing' s syndrome suggests that it is highly effective in reversd d ing the manifestations of hypercortisolism, but it is not known if the same will hold true for glucocorticoid hypersensitivity. While RUd486 has been effective in small numbers of patients treated for relatively short periods of time, the longdterm efficacy and side effects of glucocorticoid and progesterone receptor blockade remain to be determined.
The interdindividual response to glucocorticoids varies considerably; thereby diagnosis of Cushing' s synd d drome should be based on clinical suspicion. In certain circumstances, an absence of hypercortisolemia should not exclude the diagnosis of Cushing' s, as other factors at cellular levels can determine the individual response to cortisol. To date, most of these factors are still und d der investigation. Full knowledge of these factors may result in new diagnostic criteria for Cushing' s with a potential for new pharmacological therapies.
